Valsartan alleviates the blood–brain barrier dysfunction in db/db diabetic mice

References

• Chowdhury TA, Shaho S, Moolla A. Complications of diabetes: progress, but significant challenges ahead. Ann Transl Med. 2014;2(12):120.
   PubMedGoogle Scholar
• Pruzin JJ, Nelson PT, Abner EL, et al. Review: relationship of type 2 diabetes to human brain pathology. Neuropathol Appl Neurobiol. 2018;44(4):347–362.
   PubMed Web of Science ®Google Scholar
• Prasad S, Sajja RK, Naik P, et al. Diabetes Mellitus and Blood-Brain Barrier Dysfunction: An Overview. J Pharmacovigil. 2014;2(2):125.
   PubMedGoogle Scholar
• Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
   PubMed Web of Science ®Google Scholar
• Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008;32(2):200–219.
   PubMed Web of Science ®Google Scholar
• Pardo L, Valor LM, Eraso-Pichot A, et al. CREB regulates distinct adaptive transcriptional programs in astrocytes and neurons. Sci Rep. 2017;7(1):6390.
   PubMedGoogle Scholar
• Lee HT, Chang Y-C, Tu Y-F, et al. CREB activation mediates VEGF-A’s protection of neurons and cerebral vascular endothelial cells. J Neurochem. 2010;113(1):79–91.
   PubMed Web of Science ®Google Scholar
• Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98(3):1627–1738.
   PubMed Web of Science ®Google Scholar
• Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci. 2020;27(3):905–912.
   PubMed Web of Science ®Google Scholar
• Jackson L，Eldahshan W，Fagan S，Ergul A, et al. Within the brain: the renin angiotensin system. Int J Mol Sci. 2018;19(3):876.
   Web of Science ®Google Scholar
• Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340(121):b5465.
   PubMedGoogle Scholar
• Goh KL, Bhaskaran K, Minassian C, et al. Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink. Br J Clin Pharmacol. 2015;79(2):337–350.
   PubMed Web of Science ®Google Scholar
• Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65(2):809–848.
   PubMed Web of Science ®Google Scholar
• Mogi M, Li J-M, Tsukuda K, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun. 2008;375(3):446–449.
   PubMed Web of Science ®Google Scholar
• Shindo T, Takasaki K, Uchida K, et al. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer’s disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull. 2012;35(12):2141–2147.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhang F, Yu Z, et al. HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice. J Neuroinflammation. 2019;16(1):103.
   PubMedGoogle Scholar
• Mason RP, Jacob RF. Abstract MT. 648: nebivolol and valsartan increase nitric oxide release from human endothelial cells in a synergistic fashion. Hypertension. 2014;64(suppl_1):A648.
   Google Scholar
• Wang ZC, Qi J, Liu LM, et al. Valsartan reduces AT1-AA-induced apoptosis through suppression oxidative stress mediated ER stress in endothelial progenitor cells. Eur Rev Med Pharmacol Sci. 2017 Mar;21(5):1159–1168.
   PubMed Web of Science ®Google Scholar
• Chua SC Jr., Chung WK, Wu-Peng XS, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996;271(5251):994–996.
   PubMed Web of Science ®Google Scholar
• Corem N, Anzi S, Gelb S, et al. Leptin receptor deficiency induces early, transient and hyperglycaemia-independent blood-brain barrier dysfunction. Sci Rep. 2019;9(1):2884.
   PubMedGoogle Scholar
• Claflin KE, Sandgren JA, Lambertz AM, et al. Angiotensin AT1A receptors on leptin receptor-expressing cells control resting metabolism. J Clin Invest. 2017;127(4):1414–1424.
   PubMed Web of Science ®Google Scholar
• Yan J, Zhang Z, Shi H. HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells. Cell Mol Life Sci. 2012;69(1):115–128.
   PubMed Web of Science ®Google Scholar
• Sajja RK, Prasad S, Cucullo L. Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line. Fluids Barriers CNS. 2014;11(1):8.
   PubMedGoogle Scholar
• Brown RC, Morris AP, O’Neil RG. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res. 2007;1130(1):17–30.
   PubMed Web of Science ®Google Scholar
• Ichiki T. Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both? Arterioscler Thromb Vasc Biol. 2006;26(3):449–455.
   PubMed Web of Science ®Google Scholar
• Chava KR, Tauseef M, Sharma T, et al. Cyclic AMP response element-binding protein prevents endothelial permeability increase through transcriptional controlling p190RhoGAP expression. Blood. 2012;119(1):308–319.
   PubMed Web of Science ®Google Scholar
• Takhellambam SD, Lalit PS, Ken-Ichi H, et al. GSK-3beta/CREB axis mediates IGF-1-induced ECM/adhesion molecule expression, cell cycle progression and monolayer permeability in retinal capillary endothelial cells: implications for diabetic retinopathy. Biochim Biophys Acta. 2011;1812(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Liu C, Ke P, Zhang J, et al. Protein kinase inhibitor peptide as a tool to specifically inhibit protein kinase A. Front Physiol. 2020 Nov;25(11):574030.
   Google Scholar
• Costes S, Broca C, Bertrand G, et al. ERK1/2 control phosphorylation and protein level of cAMP-responsive element-binding protein: a key role in glucose-mediated pancreatic β-cell survival. Diabetes. 2006 Aug;55(8):2220–2230.
   PubMed Web of Science ®Google Scholar
• Arjmand Abbassi Y, Mohammadi MT, Sarami Foroshani M, et al. Captopril and valsartan may improve cognitive function through potentiation of the brain antioxidant defense system and attenuation of oxidative/nitrosative damage in STZ-Induced dementia in rat. Adv Pharm Bull. 2016;6(4):531–539.
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Chen L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer's disease. J Clin Invest. 2007;117(11):3393–3402.
   PubMed Web of Science ®Google Scholar
• Ho JK, Nation DA. Neuroimaging, Memory is preserved in older adults taking AT1 receptor blockers. Alzheimers Res Ther. 2017;9(1):33.
   PubMedGoogle Scholar
• Kuan YC, Huang K-W, Yen D-J, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension. Int J Cardiol. 2016;220:462–466.
   PubMed Web of Science ®Google Scholar